Logo Kérwá
 

In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom.

dc.creatorLedsgaard, Line
dc.creatorLaustsen, Andreas Hougaard
dc.creatorPus, Urska
dc.creatorWade, Juli S.
dc.creatorVillar, Pedro
dc.creatorBoddum, Kim
dc.creatorSlanvy, Peter
dc.creatorMasters, Edward W.
dc.creatorArias Oviedo, Ana Silvia
dc.creatorOscoz, Saioa
dc.creatorGriffiths, Daniel T.
dc.creatorLuther, Alice M.
dc.creatorLinholm, Majken
dc.creatorLeah, Rachael A.
dc.creatorMøller, Marie Sofie
dc.creatorAli, Hanif
dc.creatorMcCafferty, John
dc.creatorLomonte, Bruno
dc.creatorGutiérrez, José María
dc.creatorKaratt Vellatt, Aneesh
dc.date.accessioned2023-01-06T16:03:36Z
dc.date.available2023-01-06T16:03:36Z
dc.date.issued2022
dc.description.abstractThe monocled cobra (Naja kaouthia) is among the most feared snakes in Southeast Asia due to its toxicity, which is predominantly derived from long-chain α-neurotoxins. The only specific treatment for snakebite envenoming is antivenom based on animal-derived polyclonal antibodies. Despite the lifesaving importance of these medicines, major limitations in safety, supply consistency, and efficacy create a need for improved treatments. Here, we describe the discovery and subsequent optimization of a recombinant human monoclonal immunoglobulin G antibody against α-cobratoxin using phage display technology. Affinity maturation by light chain-shuffling resulted in a significant increase in in vitro neutralization potency and in vivo efficacy. The optimized antibody prevented lethality when incubated with N. kaouthia whole venom prior to intravenous injection. This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinices_ES
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.identifier.citationhttps://www.tandfonline.com/doi/full/10.1080/19420862.2022.2085536es_ES
dc.identifier.doidoi.org/10.1080/19420862.2022.2085536
dc.identifier.issn1942-0862
dc.identifier.urihttps://hdl.handle.net/10669/88023
dc.language.isoenges_ES
dc.rightsCC0 1.0 Universal*
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.sourcemAbs 14 (2022), 2085536.es_ES
dc.subjectmonoclonal antibodyes_ES
dc.subjectneurotoxines_ES
dc.subjectVENENOS ANIMALESes_ES
dc.subjectSnake venomes_ES
dc.subjectSUSTANCIA PELIGROSAes_ES
dc.titleIn vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom.es_ES
dc.typeartículo originales_ES

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022_Antivenenos_MAbs_Ledsgaard_human_monoclonal_antibody_Naja_improvement.pdf
Size:
2.55 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.5 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections